Analysis of factors influencing blood transfusion and hematopoietic reconstitution in patients undergoing allogeneic hematopoietic stem cell transplantation
10.13303/j.cjbt.issn.1004-549x.2026.09.012
- VernacularTitle:异基因造血干细胞移植患者输血及造血重建影响因素分析
- Author:
Rong WANG
1
;
Qing LIU
2
;
Zifan MENG
1
;
Shaoqiang ZHANG
1
Author Information
1. Department of Blood Transfusion, The Affiliated Hospital of Qingdao University, Qingdao 266000, China
2. Department of Clinical Laboratory, The Affiliated Hospital of Qingdao University, Qingdao 266000, China
- Publication Type:Journal Article
- Keywords:
allogeneic hematopoietic stem cell transplantation;
blood transfusion;
hematopoietic reconstitution;
CD34+ cells
- From:
Chinese Journal of Blood Transfusion
2026;39(9):1246-1253
- CountryChina
- Language:Chinese
-
Abstract:
Objective: To show the characteristics of blood component transfusion and differences in hematopoietic reconstitution time among patients undergoing allogeneic hematopoietic stem cell transplantation (allo-HSCT) retrospectively, with the aim of identifying factors affecting blood transfusion and hematopoietic reconstitution, and providing evidence for optimizing stem cell collection strategies and developing individualized transfusion regimens. Methods: A total of 95 patients who received allo-HSCT treatment in our hospital from January 2023 to December 2025 were enrolled. Data including disease classification, HLA matching status, ABO blood group compatibility, and cellular composition of grafts were analyzed, and differences in red blood cell and platelet transfusion requirements, as well as the hematopoietic reconstitution time, were compared among groups. Factors affecting transfusion requirements and hematopoietic reconstitution time were evaluated. Results: Different disease classifications showed no significant effect on red blood cell or platelet transfusion requirements. No statistically significant differences were observed in blood component transfusion volumes or hematopoietic reconstitution time between HLA semi-matched and fully matched status, ABO blood group compatibility, and graft platelet count. A statistically significant difference was observed only in granulocyte engraftment time between the graft MNC count group of (6-10)×10
/kg and the (2-4)×10
/kg group [12.00 (11.00, 13.00) vs 18.00 (17.00, 30.00) days, P<0.05]. Regarding graft CD34
cell count, the (6-10)×10
/kg group had a platelet transfusion volume of 3.00 (3.00, 4.00) therapeutic units, with granulocyte and platelet engraftment time of 11.00 (10.25, 13.75) days and 12.00 (11.00, 14.00) days, respectively; the (>10)×10
/kg group had corresponding values of 3.00 (2.00, 3.25) therapeutic units, 11.50 (10.00, 12.00) days, and 12.00 (11.00, 13.00) days. Compared with the (2-4)×10
/kg group [6.00 (3.00, 8.00) therapeutic units, 13.00 (12.00, 15.00) days, 15.00 (15.50, 22.50) days], all these differences were statistically significant (P<0.05). Patients in the CD34
<4×10
/kg group demonstrated delayed granulocyte and platelet engraftment and significantly increased platelet transfusion requirements. Conclusion: The CD34
cell dose in the graft is a significant correlate of hematopoietic reconstitution time after allo-HSCT and is significantly associated with platelet transfusion requirements. Blood transfusion is a necessary measure for supportive treatment of allo-HSCT patients. Optimizing stem cell harvesting protocols to achieve the target CD34
cell dose, along with developing individualized transfusion strategies based on graft CD34
counts, may facilitate hematopoietic recovery, reduce transfusion burden, and ultimately improve patient outcomes after transplantation.
